Clinical data | |
---|---|
Other names | MDL-18962; Propargylestrenedione; PED; 10-(2-Propyn-1-yl)estr-4-ene-3,17-dione; 10-Propargylestr-4-ene-3,17-dione |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C21H26O2 |
Molar mass | 310.437 g·mol−1 |
3D model ( JSmol) | |
| |
|
Plomestane ( INN , USAN ; former developmental code name MDL-18962; also known as propargylestrenedione, PED) is a steroidal, irreversible aromatase inhibitor which was under development by Marion Merrell Dow/ Hoechst Marion Russell (now Hoechst AG) as an antineoplastic agent for the treatment of breast cancer. [1] [2] [3] [4] [5] It was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration. [5] However, development of the drug for clinical use was halted due to "technical issues" and it was never marketed. [6]
In addition to its activity as an aromatase inhibitor, plomestane has weak androgenic properties. [5]